HCW Biologics (NASDAQ:HCWB) Stock Price Down 1.9%

HCW Biologics Inc. (NASDAQ:HCWBGet Rating)’s stock price traded down 1.9% on Friday . The company traded as low as $1.97 and last traded at $2.04. 105,992 shares changed hands during trading, an increase of 216% from the average session volume of 33,561 shares. The stock had previously closed at $2.08.

Analysts Set New Price Targets

Separately, Jonestrading assumed coverage on HCW Biologics in a research report on Monday, November 7th. They set a “buy” rating and a $8.00 price target for the company.

HCW Biologics Price Performance

The company has a debt-to-equity ratio of 0.15, a quick ratio of 12.52 and a current ratio of 12.52. The business has a 50-day simple moving average of $2.07 and a two-hundred day simple moving average of $2.25.

HCW Biologics (NASDAQ:HCWBGet Rating) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.14) EPS for the quarter.

Institutional Investors Weigh In On HCW Biologics

Several large investors have recently made changes to their positions in HCWB. HighTower Advisors LLC boosted its holdings in shares of HCW Biologics by 2,056.0% in the 1st quarter. HighTower Advisors LLC now owns 215,598 shares of the company’s stock valued at $588,000 after buying an additional 205,598 shares during the last quarter. BlackRock Inc. boosted its holdings in shares of HCW Biologics by 136.8% in the 1st quarter. BlackRock Inc. now owns 39,583 shares of the company’s stock valued at $108,000 after buying an additional 22,869 shares during the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of HCW Biologics by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 95,392 shares of the company’s stock valued at $218,000 after buying an additional 8,494 shares during the last quarter. Institutional investors and hedge funds own 1.83% of the company’s stock.

HCW Biologics Company Profile

(Get Rating)

HCW Biologics Inc, a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases.

Further Reading

Receive News & Ratings for HCW Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCW Biologics and related companies with MarketBeat.com's FREE daily email newsletter.